ANAHEIM, CA--(Marketwired - Oct 17, 2017) - BioCorRx Inc. (
Brady Granier, President & CEO of BioCorRx, stated, "According to an alarming study published in the September 2017 issue of JAMA Psychiatry, one in eight American adults now meet the diagnostic criteria for alcoholism. Further, nearly one in four adults under age 30 meets the diagnostic criteria for alcoholism. Alcohol use disorder (AUD) rose by 49 percent in the first decade of the 2000s, and now affects 12.7 percent of the American population. Our program, the BioCorRx Recovery Program, combines a compounded naltrexone implant per patient prescription with structured, proprietary cognitive behavioral therapy (CBT) modules, as well as peer support. Our company was originally founded primarily for the treatment of alcohol use disorder which is a larger problem, when compared to other substance use disorders, yet doesn't get the attention it deserves. We have seen some very amazing transformations over the years from those participating in our program for AUD. We encourage those families and individuals suffering to give our program a closer look."
About BioCorRx
BioCorRx Inc. (
Safe Harbor Statement The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc. investors@BioCorRx.com 714-462-4880 Investor Relations: Crescendo Communications, LLC (212) 671-1020 x304 bicx@crescendo-ir.com
